Treatment of Atopic Dermatitis with Tralokinumab, an Anti –IL-13 Monoclonal Antibody

Our data provide evidence for targeting IL-13 alone in atopic dermatitis. Tralokinumab demonstrated meaningful improvements in Eczema Area and Severity Index and Investigator ’s Global Assessment responses, with additional benefits in participants with increased IL-13 activity.

Source: Journal of Allergy and Clinical Immunology - June 12, 2018 Category: Allergy & Immunology Authors: Andreas Wollenberg, Michael D. Howell, Emma Guttman-Yassky, Jonathan I. Silverberg, Christopher Kell, Koustubh Ranade, Rachel Moate, Ren é van der Merwe Source Type: research